Skip to main content
. 2020 Dec 31;22(1):387. doi: 10.3390/ijms22010387

Figure 3.

Figure 3

A 644 AHR-driven gene signature correlates with survival in eight human cancers. (a) Top: Western blotting for AHR protein in AHR knockout (KO), wildtype (WT) or Cas9 control SUM149 triple negative inflammatory human breast cancer cells or MDA-MB-231 triple negative human breast cancer cells. Bottom: Quantification of β-actin normalized band densities. Data are presented as means + SE from three independent experiments. No significant differences (ns) were found between WT and Cas9 (transfected with Cas9 but not guide RNA) control cells. **** p <0.00001 compared to WT or Cas9 controls. (b) Affymetrix whole human genome microarrays were used to determine transcriptional profiles of Cas9 control or AHR knockout SUM149 or MDA-MB-231 cells. Genes differentially expressed upon AHR knockout were identified across cell types. A significant decrease after AHR knockout was defined as an adjusted false discovery rate (q value) of ≤0.05. (c) The 644 AHR-driven gene signature in “b” was correlated with survival for the eight cancers in Figure 1 using TCGA data and Gene Set Variation Analysis (129).